CA1326268C - Transport of molecules across tissue using electroporation - Google Patents

Transport of molecules across tissue using electroporation

Info

Publication number
CA1326268C
CA1326268C CA000588839A CA588839A CA1326268C CA 1326268 C CA1326268 C CA 1326268C CA 000588839 A CA000588839 A CA 000588839A CA 588839 A CA588839 A CA 588839A CA 1326268 C CA1326268 C CA 1326268C
Authority
CA
Canada
Prior art keywords
tissue
electroporation
electrical
molecules
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000588839A
Other languages
French (fr)
Inventor
James C. Weaver
Kevin T. Powell
Robert S. Langer, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of CA1326268C publication Critical patent/CA1326268C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A61B5/14514Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0412Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0412Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416Anode and cathode
    • A61N1/0424Shape of the electrode
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0428Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432Anode and cathode
    • A61N1/044Shape of the electrode

Abstract

TRANSPORT OF MOLECULES ACROSS
TISSUE USING ELECTROPORATION

Abstract of the Disclosure An electrical process for enhancing and/or controlling transport of molecules across tissue such as human and animal skin is disclosed. The process involves the use of a high voltage, short duration electrical pulses on the tissue surface to produce electroporation. Once this effect has oc-curred, concentration, pressure or temperature gradients, or iontopheresis can be used to move molecules across the tissue. The process can be repeatedly applied without producing undesirable tissue damage or can be used to purposely cause highly limited tissue damage for the purpose of providing a desired, relatively long term molecular transport pathway. The occurrence of the electro-poration effect can be detected by monitoring the tissue for a reversible electrical breakdown, which, along with an enhanced tissue permeability, is the characteristic effect of electroporation.

Description

`

-` ~ 326268 TRANSPORT OF MOLECULES ACROSS
TISSUE USING ELECTROPORATION
Description - Background of the Invention 05 Molecules such as drugs, nutrients and metabo-lites are not easily transported into, out of and across tissue, because tissue consists of a variety of cells, often of different types, which must be ~ traversed by molecules. A healthy tissue, perfused ;~10 by blood, is readily supplied with nutrients and often well supplied with blood-borne drugs. Addi-tionally, metabolic products are generally effi-ciently removed by the circulatory system.
!^Unfortunately, the ability to deliver or remove ;115 compounds through tissue surfaces is generally rela-tively poor. Likewise, the ability to cause or control the delivery of compounds across tissue, from one surface to another, is relatively poor.
The flux of molecular transport through a tissue is a function of the product of the tissue permeability, the driving force and the area of the tissue. In most early attempts to increase the uptake of pharmaceuticals in living organisms, permeability factors have been the focus as a means of increasing flux. These attempts have focused on providing pharmaceutical compounds to regions of tissue having a natural permeability higher than ; that found naturally in skin. Such relatively high permeaoility tissues include tissue of the stomach -, . . . :

' , . .

and intestines, rectal tissue, buccal tissue, sinus tissue, lung tissue and the interstitial tissue below the surface of the skin.
The most common method of using highly 05 permeable tissue for pharmaceutical administration is oral ingestion. This method contacts the pharma-ceutical to be administered with the highly perme-able stomach lining and intestinal walls. While this route is acceptable for a wide variety of drugs, it has drawbacks which render it less than ideal for some drugs and completely unacceptable for others. These drawbacks include the inability to alter the driving force for controlling transport flux, the likelihood of drug breakdown (due to digestive processes) prior to absorption into the bloodstream, and high first pass liver metabolism or liver toxicity.
The most common method for utilizing the highly permeable interstitial tissue below the skin surface to transport pharmaceuticals is by injection, using either a hypodermic needle or an injection gun.
While these methods offer the advantage of quickly placing the drug into the patient's interstitial fluids, many patients, especially children, find injection to be a painful and unpleasant experience.
Furthermore, for drugs which are administered frequently or continuously, needle injection sites are subject to high rates of infection.
Like injection, in which the skin is physically breached to expose tissue having a greater perme-ability than that on the surface, drugs can also be -administered to interstitial tissue through surface abrasion of the tissue. This method was commonly used in past as the method of smallpox vaccine administration. In addition to the pain and dis-05 comfort of this method, abrasion often results inthe formation of unsightly scar tissue at the abrasion site.
In some instances, the tissue has a perme-ability which is high enough for the administration of certain drugs. In these cases, administration can occur by topical application of the drug. This can be accomplished either by rubbing a compound containing the drug onto the skin surface, or by inserting a material containing the drug into a body orifice, as in the case of suppositories. While this method is painless and has found a variety of uses (notably transdermal patches for nitroglycerine and motion sickness drugs) topical application for drug delivery suffers from the slow rate at which transtissue absorption occurs. Thus, for drugs in which it is acceptable to administer low dosages over prolonged periods of time, topical application can prove useful. However, for the vast majority of drugs, this mekhod is not satisfactory due to the low rate at which the drug is absorbed.
The permeability of tissue such as skin can be elevated above its natural state through the use of absorption enhancers. These are generally penetrat-ing solvents, which, when combined with a drug and applied to the skin, greatly increase drug , ~ 4 - 1 326268 absorptlon through the skin. An example of one such enhancer is dimethyl sulfoxide (DMSO).
In each of the examples above, tissue -` having natural or chemically-enhanced high permeability has been utilized as a means of increasing the flux of the transported molecule.
The flux of molecules across tissues can be further enhanced by increasing the driving force on - the molecules. Such driving forces include pressure gradients, concentration gradients and pressures such as acoustic pressure. Additionally, the use of external electromagnetic fields, as in the case o~
iontopheresis, can be used as a means to increase the driving force.
Iontopheresis utilizes an electrical current to drive positive or negative ions into i tissue. See, for example, U.S. Patent 4,141,359 " (February 27, 1979) of Jacobsen et al.; U.S. Patent 4,250,878 (February 17, 1981) of Jacobsen et al., 20 U.S. Patent 4,474,570 (October 2, 1984) of Ariura et al.; U.S. Patent 4,557,723 (December 10, 1985) of Sibalis; U.S. Patent 4,622,031 (November 11, 1986) of Sibalis; U.S. Patent 4,639,244 (January 27, 1987) of ~ Rizk et al.; and Sloan et al., J. Am. Acad. Derma-j 25 tology, 15, 671-684, 1984. In this method, two or q more electrodes are placed into contact with the - tissue. At least one of the electrodes is a pad of ~-J, absorbent material soaked with a solution of the drug . to be administered. When a low voltage is applied i 30 across the tissue, the ~ .

~ .
:, ,, . ' , , ~' , , . ~ ' .

,:
', - ; ' .

r ---s ions of the drug move to the electrode of the opposite charge, and in so doing penetrate the tissue. Neutral molecules can be moved, although to a lesser extent, by a phenomenon known as solvent 05 drag in the solution. As lonq as the voltage is applied, the process will continue with transport abruptly decreasing when the driving force of electrical potential is discontinued.
While these are amon~ numerous methods for increased transport molecule flux by altering or selecting tissue to exhibit high permeability and by selecting various driving forces, a need still exists for a method in which molecules can be transported across tissue at a more rapid, controlled rate, but in a manner which significantly damages neither the molecules nor the tissue and which, when used in vivo, produces little pain and discomfort for the patient.
It is known that the permeability of isolated, widely separated, individual cell membranes can be temporarily increased and the electrical resistance decreased by the process of electroporation and the associated phenomenon of reversible electrical breakdown (REB). See, for example, Neumann et al., J. Membrane Biol., 10, 279-290, 1972 (electropora-tion); and, Zimmermann et al., BiophYsical J., 14, 881-899, 1974: Zimmermann et al., Biochim. BioPhYs.
Acta, 375, 209-219, 1975; Zimmermann et al., Rev.
PhYsiol. Biochem. Pharmacol., 105, 175-256, 1986;
U.S. Patent 4,081,340 (March 28, 1978) of Zimmermann et al; and U.S. Patent 4,220,916 (September 2, 1980) of Zimmermann et al. (reversible electrical break-` - 6 ~ 1 32 626 8 down). In this method, a solution containing isolated, individual cells and large molecules such as DNA or enzymes are subjected to a high voltage pulse of short duration. When examined after the pulse, some cells are found to contain the large molecules. In cells that take up DNA some expression has been observed. However, the fraction of cells transformed by electroporation is generally found to be small, for example 10 5 to 10 4. setter results have been found in a few cases in which about 1% of electroporated cells have shown uptake, DNA transport into the cell nucleus, incorporation, expression and ~ survival. See, for example, Neumann et al., EMBO J., i 1, 841,845, 1982; Potter et al., PNAS, 78, 7161-7165, 1984; Toneguzzo et al., Molecular and Cellular Bio., 6, 703-706, 1986; Chu et al., Nucleic Acids Research, 15, 1311-1326, 1987; Stopper et al, Biochim. Biophys.
Acta, 900, 38-44, 1987; and Toneguzzo et al., Proc.
9th IEEE/Engineering In Medicine and Biology Society, 715-716, 1987. Additionally, electroporation of isolated red blood cells has shown that approximately ; 20% of the electroporated cells dramatically change shape from biconcave disks to spheres and take up relatively uncharged dextran molecules. See Weaver et al., Proc. 9th IEEE/Engineering in Medicine and Biology Societv, 708-709, 1987.

, , ' .

~ 7 - ~ 32 6268 Prior work indicates that only relatively uncharged molecules, such as dextrans, have been readily introduced into, or released from, individual cells by electroporation, and there is some evidence suggesting that charged molecules are difficult to introduce. See, Sowers et al., FEBS Lett., 205, 179-184, 1986. Furthermore, the present method of introducing DNA into individual cells by electro-poration results in survival of only about 40-80% of the cells. See Potter, Proc. 9th IEEE/Engineering in Medicine and Biology Society, 705-707, 1987. This survival rate is acceptable if only a few clones are needed.
Previous studies of the behavior of electrically pulsed tissue have often revealed very significant destruction. See, Lee et al., Proc. 9th IEEE/Engineering in Medicine and Biology Society, 712-714, 1987; and Lee et al., Plastic and Recon-struct. Surg., 663-671, November 1987. There is no evidence to indicate that electrical pulses have been studied as a means of producing electroporation to ; increase permeability and molecular transport in tissues such as skin.

Summary of the Invention This invention pertains to a process whereby it is possible to increase and control transport of -.

~ 1 326268 molecules across tissues includiny human and animal skin and muccosal membranes such as rectal, vaginal and buccal membranes using the process of electro-poration to increase the tissue permeability.
05 This invention further pertains to a process for transporting molecules across tissue comprising the steps of:
a) applying one or more pulses of electrical energy of sufficient voltage and duration to a region of a tissue in order to cause electropora-tion, thereby producing a transient increase in tissue permeability; and b) utilizing a driving force to move molecules across the regions of the tissue undergoing electro-poration.
The driving force to move molecules across thepermeabilized tissue may be electrical, such as in the case when iontopheresis is used, or it may be another physical or chemical force such as provided by a temperature gradient, a pressure gradient, or a concentration gradient. Additionally, the driving force may comprise acoustic or optical pressure.
Problems of transporting sufficient numbers of molecules into, out of, or across a tissue can be overcome using electroporation, via the transient high permeability state. An effect, repeatedly observed in tissues undergoing electroporation, called reversible electrical breakdown (REB), can be used to provide an indication of the occurrence of electroporation, thereby providing a basis for selecting the magnitude, duration and shape of the electrical pulse or pulses. The transient high permeability state can be used to increase the transport flux of molecules in conjunction with a driving force such as concentration difference and `~ hydrostatic pressure. Thus, for example, the stratum S corneum barrier of skin can be circumvented by ` causing electroporation to occur on the inner walls of hair follicles and sweat ducts, thereby allowing molecular transport into the interstitial fluids underlying the stratum corneum.
An advantage of this process is the ability to increase tissue permeability. This process is also useful for moving molecules whose driving force cannot be increased. Such molecules include, for example, non-ionic molecules or molecules near their saturation concentration. The process can also provide the ability to select operating conditions that result in little or no permanent effect on the tissue caused by the temporary or transient increased tissue permeability of the process.
In accordance with a further embodiment of the invention there is provided a method for temporarily transporting molecules across tissue comprising the steps of:
a) applying at least one electrical pulse of sufficient voltage and duration to a region of tissue, wherein the tissue comprises at least a single layer of cells, in order to cause electro-poration in the region; and b) utilizing a driving force to move molecules across the regions of the tissue undergoing electro poration.

Brief Description of the Figure i Figure 1 is a schematic representation of an apparatus useful for transporting molecules across a tissue using enhanced tissue permeability induced by electroporation.

.

-' ~ ' ~ -, - 1 32626~
- 9a -Figure 2 is a schematic representation of an apparatus useful for transporting interstitial fluids to the surface of a tissue using enhanced tissue permeability induced by electroporation.
igure 3 is an arbitrary graphic representation of electrical potential versus time for a series of electrical pulses of varying potential and duration wben applied to a tiasue.

.i. ~. ., Detailed Description of the Invention The phenomenon of electroporation is charac-terized by several sub-phenomena, including a transient high permeability state and reversible 05 electrical breakdown (REB). REB is characterized by a decrease in the electrical resistance of a tissue which is caused by brief exposure to an abnormally high transtissue potential. Electroporation has been observed in artificial planar bilayer membranes stretched across a macroscopic opening in materials such as poly(tetrafluorethylene), as well as in cell membranes wherein cells are either punctured with a microelectrode or suspensions of cells are exposed to an external electrical field. REB has been demonstrated and studied using either the artificial bilayer membrane, a micropunctured cell, and in cell suspensions using a version of a Coulter counter.
In contrast, the present invention is useful for producing and utilizing the effects of electropora-tion in both plant and animal tissue, and is based on a transient high permeability state. The inven-tion can be used with or without detection or measurement of the REB phenomenon occurring at the beginning of the high permeability state.
Electroporation in some or all of the cells in a region of a tissue is caused by short, high voltage electrical pulses applied to the tissue surface or to an underlying tissue region resulting in a transient state of increased tissue perme-ability. A decreased electrical resistance associ-ated with REB is a further result of electroporation and can be used as an effective means of monitoring electroporation effects.

:
1 32626~

These results can be demonstrated in a tissue by producing electroporation (and REB) in the following manner:
Short electrical pulses of 10 8 to 1 sec, or 05 preferably 10 6 to lO 3 s, are applied to a tissue sample. At a fixed pulse width, the resistance of the sample will remain virtually unchanged as the voltage magnitude of electrical pulses is increased.
Above a certain threshold, however, the resistance rapidly decreases, with higher voltage pulses further decreasing the tissue resistance. This is the characteristic demonstration of electroporation-- induced REB, which previously has been demonstrated only for artificial planar bilayer membranes, for micropunctured cells, or for bacteria in a Coulter counter which simultaneously flows isolated cells and an electrical current through an insulating orifice.
Following REB, the transtissue resistance can gradually recover to its initial value. This is similar to previous work on artificial bilayer membranes or individual cell membranes, wherein ; recovery times have been found to range from micro-seconds in the case of artificial planar bilayer membranes up to minutes, or more in the case of biological membranes. Furthermore, unlike the case i in which longer pulses of lower voltage magnitude are applied to an artificial bilayer membrane, REB
caused by electroporation often avoids membrane rupture or irreversible electrical breakdown.
The transmembrane potentials associated with electroporation and RE8 are in the range of about .

" , ~ :
, "' ' ',' ' '' ' 500 to about 1,500 mV. This is much higher than the normal physiological resting potential of about 100 mV and generally above the magnitude of trans-membrane potentials known to result in membrane 05 rupture (about 300 to 600 mV). Thus, the relatively short duration of the electrical pulses used to induce electroporation and REB is a key aspect of the process. Previous studies of electroporation have observed the effect only in individual cells such as red blood cells, squid axons, squid eggs, and giant algae cells. The present invention shows that electroporation can be demonstrated in multi-layer tissues such as living frog skin, rat skin and underlying tissue, hairless mouse skin and under-lying tissue, and in surgically removed human skinand underlying tissue. Generally, for cells, the occurrence of electroporation, as evidenced by REB, results in non-thermal, short term membrane changes, with all damage or death occurring only due to long j 20 term osmotic pressure differences, or other physio-chemical imbalances between the inside and outside of a cell experiencing the high permeability state.
However, it may be possible to provide conditions, such as iso-osmotic bathing solutions, which minimize tissue damage.
Alternatively, if it is desired to kill or permanently damage some of the cells in order to provide a longer-lasting molecular transport pathway in tissue, a combination of electrical pulse condi-tions and bathing solution conditions can beselected to result in some cell lysis. For example, -, ' an extreme case relates to delayed, non-thermal r tissue damage associated with electrocution acci-dents, wherein it is now appearing that the un-desirable aspects of electroporation phenomena can 05 result in significant tissue destruction.
Damage of tissue by cell lysis and by cell fusion can occur for some pulse conditions which induce electroporation and REB. However, it has been demonstrated that electroporation can 10 repeatedly be produced in tissue without causing any significant cell lysis, and while cell fusion has not been investigated directly, no harmful effects attributable to cell fusion have been discovered.
Thus, repeated electroporation, as demonstrated 15 through the occurrence of REB of biological tissue, can be essentially harmless to the tissue itself, or to the organism in the case of in vivo induced electroporation.
The fact that electroporation can be repeatedly 20 produced in animal tissue to increase permeability without damaging the tissue is advantageous in that it allows electroporation to be used as a method to increase molecular transport into and/or across biological membranes. A tissue consisting of living 25 cells can be regarded as a multilayered series of individual sheets. Electroporation can be produced in any single sheet by applying a short (i.e., 1-l,000 us) pulse of about 1 to 3 volts across the sheet. This results in electroporation of cells in 30 the sheet, which can be revealed by the occurrence of REB, and allows, through the temporary high ; , '' ' ~. . ' ~ -permeability state, increased molecular transport through the sheet.
A more complex tissue can be approximated as a multilayered series of such individual sheets.
05 Because a single sheet requires approximately 0.1 to 5 volts and preferably 1 to 3 volts to achieve - increased molecular transport, a thicker membrane (e.g., approximately 20 sheets) would require a pulse of, at most, about 20 to about 60 volts and 10 is less when electroporation occurs first at one layer, such that the full potential difference then appears across the remaining layers. This higher voltage itself does not, however, damage the tissue because on the scale of the individual cell layer, 15 it is between only 1 and 3 volts.
Essentially all previously published informa-tion regarding electroporation, particularly the r occurrence of a high permeability state, and also ' the detection and measurement of REB, has been 20 obtained from studies on artificial planar bilayer membranes, or from widely separated cells which are suspended in an aqueous electrolyte medium. Based on these studies on non-tissue samples, electropora-tion is believed to be caused by a temporary cre-25 ation or enlargement of pores present in an artifi-cial bilayer or cell membrane caused by a sudden intense pulse of transmembrane potential. The enlarged pore size results in greatly decreased electrical and molecular transport resistance across 30 the membrane. Following electroporation, the en1arged pores gradually return to their n-rmal ;
,, ,, , size, resulting in a resistance which gradually increases to its initial value. While the pores are enlarged, however, it is possible to transport both charged ions and neutral molecules across the cell 05 membrane using conventional transport driving forces such as iontopheresis, concentration differences and pressure differences. Once the pore size has decreased to the initial state, the process may be repeated to provide further transport.
An important application of molecule transport into and through tissue relates to non-invasive interstitial fluid chemical assays, and to drug delivery across the skin.
Transdermal pharmaceutical delivery has tradi-tionally been problematic due to the presence of thestratum corneum. The stratum corneum is a sheet of essentially dead cells which exist on the outside of the skin. Both sweat gland ducts and hair follicles interrupt the stratum corneum essentially by perforating it. Dry stratum corneum is well known to be relatively impermeable to water soluble substances. As such, the outermost skin layer, consisting of dry stratum corneum, does not readily lend itself to a process in which the pores of hydrated membranes are enlarged. Thus, it would appear that electroporation is not compatible with transdermal drug transport.
Problems of this type are overcome, however, by the previously discussed fact that the stratum corneum is interrupted by both sweat gland ducts and hair follicles. Often some fluxes of drugs can be iontophoretically passed across the skin without use of electroporation, but increased fluxes of drugs can be diffusively, convectively (by pressure) or iontophoretically moved through sweat gland ducts if the barrier between the interior of the ducts and 05 the interstitial fluid is made more permeable. This is precisely the effect observed on the cell lining of the duct when electrical pulses characteristic for causing electroporation, which can be detected by the occurrence of REB, are applied to the skin.
Further~ore, early studies suggest that bar-riers such as sweat ducts and especially duct linings are preferentially susceptible to perme-ability modification by electroporation when elec-trical pulses are applied to the skin surface. This is due to the fact that the sites of primary resistance to delivery of water soluble molecules are also the sites of the major electrical resis-` tance. The result is that electrical pulses applied from relatively distant electrodes will produce the largest transmembrane potential difference changesof tissue cells at the very site at which electro-poration permeability increase is most desired. In the case of sweat gland ducts, and other structures which have the attribute of a tube lined by cells connected by tight junctions, the local relatively high electrical resistance results because of both the approximate cylindrical geometry of the duct, and because of the relatively high electrical resistance of a cell layer with cells connected by tight junctions.
Thus, in practice, an electrical pulse charac-teristic of inducing electroporation, detected by , .

., measuring the occurrence of REB, can be applied to the skin surface. This results in electroporation of cell membranes at the tissue comprising the walls of the sweat ducts. Conventional iontopheresis, 05 concentration difference or pressure difference techniques can then be used as a driving force to transport pharmaceuticals across the sweat duct wall and into the interstitial fluids lying beneath the stratum corneum. Hair follicles may be approached in a manner similar to that of sweat glands.
Depending on the state of activity of the sebaceous glands, the hair follicles may offer a second pathway for transdermal drug delivery.
Likewise, a process similar to the above can be used for non-invasive sampling of interstitial fluid for chemical assay. The only significant difference is that outward driving forces, such as negative pressure, can be applied to the skin surface, so as to draw out small amounts of interstitial fluid through the molecular transport pathways caused, or increased in permeability by electroporation.
In one embodiment of the invention, non-polar-izable electrodes, such as conventional electro-cardiograph electrodes constructed from conventional silver/silver chloride contacting a gel or paste, such as physiological saline, are used. Alterna-tively, electrodes constructed of stainless steel, platinum or gold can be used. At least one of the electrodes is located in close proximity to a reservoir containing the compound whose transport into or across the tissue is desired.

-18- l ~26268 Alternatively, for non-invasive sampling, the transport of endogenous tissue compounds can be altered by locating a collection region or chamber near at least one of the electrodes.
05 A source of electrical potential, capable of generating a series of short electrical pulses of the type sufficient to induce electroporation is connected to at least two electrodes, allowing potentials of suitably short duration. In one embodiment, the pulses are approximately "square wave" in nature, with a duration of width ranging from about 10 8 s to about 1 s. In other embodi-ments, the pulses are saw tooth, triangular, ex-ponential or sine wave in nature, again with a duration of width ranging from about lO 8 s to about 1 s. In the preferred embodiment, pulse width ranging from about 10 6 s to about 10 3 s is used to produce REB and thereby to indicate the occurrence of electroporation.
The magnitude of the pulses is selected to correspond to that needed to produce electroporation and REB across the particular tissue being energized. Generally this voltage will be in the range of about 20 V to about 2,000 V, with a range 25 of about 50 V to about 750 V being more likely.
When the tissue contains many cell layers as in the case of human skin, these voltages, applied for short periods, produce a transmembrane potential of about 0.5 V to about 3 V on each cell layer. The voltage actually selected will depend upon the tissue properties of the electroporation site, which, in the case of human skin, for example, can vary significantly depending on age, fat content and location on the body.
One embodiment of an apparatus for producing 05 the transient high permeability state in tissue via electroporation for the purpose of drug delivery is represented schematically in Figure 1. In Figure 1, the apparatus, represented generally as 10, com-prises an electrical pulse generator 12, a control-ler 14, a set of two or more electrodes 16, of whichat least one has a molecule reservoir 18, and optionally, a means 20 for detecting REB.
In operation, the reservoirs 18 are filled with the molecules to be transported and the electrodes 16 are placed in contact with the surface of tissue 22. A pulse generator 12, in communication with the electrodes 16 provides an electrical pulse of a specific shape, voltage, duration and frequency to the electrodes. The shape, duration, frequency and peak voltage of the pulse are controlled by a controller 14. The pulse is gradually cycled to higher voltages until electroporation occurs. At ` that point, the pulse, shape, duration, frequency and voltage is maintained until a desirable amount of molecular transfer has occurred.
Optionally, a second set of electrodes 20, or the same electrodes 16, can be used to monitor electrical resistance through the tissue. These electrodes 20 are operatively connected to the controller 14 and serve as a means for detecting the reversible electrical breakdown occurring during electroporation Thus, they serve to inform the -" I 326268 controller 14 of the point at which pulse conditions should be maintained.
Another embodiment of the invention, a diag-nostic apparatus, is represented schematically in 05 Figure 2. In Figure 2, the apparatus, represented generally as 50, comprises an electrical pulse generator 12, a controller 14, a set of two or more electrodes 16, a container 30, optionally an electrode, having a reservoir 32, and optionally, a means 20, for detecting REB.
The apparatus operates much like that of the previous embodiment, except that instead of being useful as a means for delivering a drug, apparatus 50 is useful as a non-invasive means for collecting interstitial fluids for diagnostic purposes.
In operation, the electrodes 16 are placed in contact with the surface of tissue 22. A pulse generator 12, in communication with the electrodes 16, and optionally with an electrode-container 30, provides an electrical pulse of a specific shape, duration, voltage and frequency to the electrodes.
The shape, duration, voltage and frequency of the pulse are controlled by a controller 14. The pulse is gradually cycled to higher voltages until electro-poration occurs. At that point, the high perme-ability state allows interstitial fluids to be transported out of the tissue into the reservoir 32 of container 30. These interstitial fluids can then be used in a variety of diagnostic procedures.

~' A second, optional set of electrodes 20, operates in the same manner as in the previous embodiment.
In both Figures 1 and 2, the drug-containing or 05 fluid-collecting container can be either an elec-trode or an electrically neutral container. For example, in some embodiments, the container can be electrically neutral and used in conjunction with electrodes which may or may not contain reservoirs, 10 while, in other embodiments, the container can be incorporated into an electrode which is used in conjunction with other electrodes which may or may not contain reservoirs. Optionally, non-energized ` containers can be used with an electrode-container --- 15 as well. As such, the embodiments of the invention are not intended to be limited to those represented by Figures 1 and 2.
In yet another embodiment of the apparatus, reservoirs for the transport of molecules into s 20 tissue and for the collection of molecules trans-ported out of tissue can be employed simultaneously.
As described previously, either or both types of reservoirs can be incorporated into electrodes or can be electrically neutral and used in conjunction 25 with charged electrodes. Such an embodiment pro-vides the ability to use one pulse generator and controller to simultaneously produce both thera-peutic and diagnostic electroporation in tissue.
In the preferred process of this invention, the i 30 values and changes in values of the electrical impedance between any pair of electrodes, either during or after any pulse or pulse series, are ' , .

;- monitored to allow a determination of the occurrence of REB for any tissue transport situation. More specifically, by monitoring the electrical impedance between any pair of electrodes, preferably using a 05 low level alternating current with a frequency between 100 Hz and 10,000 Hz, the mass transport resistance associated with low molecular weight ionic species such as Na+ and Cl , which occur at naturally high concentrations in biological tissues, v 10 can be used to indicate the occurrence of REB and thereby, the occurrence of electroporation and the associated high permeability state.
Because the transdermal pharmaceutical delivery method, or interstitial fluid sampling, is con-,~- 15 trolled directly by electrical means, it is possible to program a method for precisely controlling delivery which takes into account differences in , individual skin properties, and differences in ` individual drug delivery or interstitial fluid 20 sampling needs. For example, the pulse generator can be programmed to produce short, low voltage pulses of increasing magnitude while monitoring for the occurrence of REB. The potential of the pulses is gradually incremented to a higher level until REB
, 25 is detected. At this point, the generator can supply pulses at this level, while constantly monitoring for any change in REB, making adjustments accordingly to maintain the condition. This allows the electroporation process to be precisely con-; 30 trolled, while actively avoiding an electrical condition capable of causing undesirable tissue damage.

once REB has been detected, pharmaceutical compounds can be transported across cell membranes using a conventional driving force. For example, in one embodiment of the invention, electroporatiOn is 05 induced in the membranes lining the interior of sweat ducts. The pharmaceutical is then transported through these membranes into the interstitial fluids underlying the stratum corneum surface.
Similarly, once REB has been detected, conven-tional methods, such as negative pressure, can beused to acquire interstitial fluid samples.
A number of methods for transport of molecules across the electroporated membranes are possible.
Each of these methods uses a driving force to move molecules across the temporarily permeabilized membrane. For example, in one simple method, a concentrated form of the material to be transported is held in a reservoir contacting the tissue surface at the site of electroporation. The driving forces of concentration difference in combination with an externally elevated hydrostatic pressure causes the material to pass through the enlarged tissue cell membrane pores into the underlying interstitial fluids. Once the pores have gradually retracted to their initial diameter, or a diameter below which the transport rate is too low, a new electric pulse is applied to the area to repermeabilize the tissue cell membranes.
In another embodiment, iontopheresis can be used as the driving force to transport molecules across the tissue once enhanced permeability through electroporation has occurred. In this embodiment, a ,, ~
pulse is applied to a site in order to increase permeability by inducing electroporation. Simul-taneously with, or subsequent to the detection of REB, an electrical potential of much lower voltage 05 and greater duration is applied to the electro-porated site. Ions present in this low voltage field will migrate toward sources of opposite ` charge. Thus, if an electrode is present at - another distant site, oppositely charged drug ions will migrate through the electroporated membrane into the subcutaneous, interstitial fluids. Neutral molecules can also be moved via iontopheresis by a phenomenon known as solvent drag. This results from the repeated contact of charged particles moving in one direction, such that net transport of a neutral molecular species occurs because of the transport of the electrical charge species. As with concentra-tion difference or pressure difference transport, the transport site is monitored to detect pore retraction or cell membrane recovery. When the . pores have retracted to a size at which the ; transport rate drops below a selected level, the ; continuous, low voltage field for the iontopheresis is temporarily interrupted or is maintained and a new electrical pulse having the characteristics to induce electroporation is applied.
The transport processes associated with this invention lend themselves to use with a wide variety of molecules including drugs and molecules of diagnostic interest. As used herein, the term "drug" is broadly defined to include any chemical , /

agent that affects or prevents processes in a living organism. Examples include drugs which are intended for therapy such as antibiotics, drugs which are intended for prevention such as polio vaccine, and 05 drugs which are intended for diagnosis. Similarly, molecules of diagnostic interest include both naturally occurring species such as metabolites, hormones and proteins as well as therapeutically introduced molecules.
Additionally, electroporation has been demon-strated to insert large molecules, such as enzymes and DNA, into individual cells. Thus, it is ex-pected that this method can be used to transport comparably large molecules into and/or across tissues, including particularly the skin.
The following examples are intended to more specifically illustrate the present invention.

Example I: Electrical Effects A fresh excised piece of abdominal frog skin was placed in a diffusion apparatus as a membrane between two chambers. Each chamber was filled with frog Ringer's solution comprising 100 mM NaCl, 2 mN
XCl, 2 mM CaC12, 2.4 mM NaHC03 and 10 mM dextrose.
The following electrical properties were measured:
Resistance R = 500-1000 Ohm/cm2 Capacitance C = 0.5-5 Farad/cm2 Short Circuit Current Isc = 5~50 uA
Resting Potential VOC = -20 to -100 mV
(mucosal side ground) ~ 3~6268 Each of these values was found to be in agreement with standard accepted values.
Planar stainless steel electrodes were used to apply pulses, and the resistance of the skin sample 05 was monitored using calomel electrodes or Ag/AgCl electrodes to detect the increased permeability state of electroporation and REB. REB was demon-strated in three ways.
In the first REB demonstration, electrical pulses of varying magnitude and duration were applied. Post-pulse decay of the transdermal potential was faster when pulses above threshold magnitudes or above threshold durations were applied. When decaying transdermal potentials were recorded on an oscilloscope, the traces cross when sub- and supra-threshold pulses were applied. This effect is clearly seen in Figure 3. As skin capacitance is a relatively constant value, the change in rate of electrical potential decay indi-cated decreased electrical resistance and corres-ponding increased ionic permeability of the frog skin .
In the second REB demonstration, the data for the decaying transdermal potentials of the above experiment were digitized and curve fit. The results quantified the change in resistance as occurring as a threshold event. The transdermal resistance was found to be most dependent upon the maximum transdermal potential produced by the applied pulse. It was seen that when the potential for the pulse was above a certain threshold, a large decrease in transdermal resistance was created.

1 326~68 In a third REB demonstration, low level current ramps were repeatedly applied to the skin, producing a real time measurement of skin resistance. After a single, high voltage pulse was applied (with the i 05 injected charge increasing skin potential to 1-2 volts), the transdermal resistance dropped 50-75%.
A drop of this magnitude is an indication that the skin's permeability to small ions increased between 100 and 300%, that is, an increase by a factor of two to four.
In each of these experiments, frog skin was used. Frog skin, electrically, is approximately a monolayer of cells. The applied pulses varied from l.o to 200 V with a duration varying from 1.0 to 1000 us. These conditions produced a charge injec-tion that raised the transdermal potential between 0 and 2 V. A single pulse which produced a trans-dermal potential greater than the 0.5-1.5 V
threshold was correlated with the appearance of the high permeability (REB) state. The increased permeability was transient, decreasing to its normal level after about 10-120 seconds. The effect was repeated on the tissue sample over 100 times without apparent damage.
Similar studies were conducted on tissue supplied from hairless mice, rats and human cadavers. All samples showed similar evidence of increased ion permeability (as measured from reduced electrical resistance) after pulses of high elec-trical potential were applied to the sample. While none of the mammalian tissue samples showed as . JJ ' ' ' . .

dramatic a resistance decrease as frog skin, the effect was still seen in each case. This is likely due to the fact that unlike frog skin, the mammalian tissue consists of a series of tissue layers rather 05 than a single layer.

Example 2: Control for Radioisotope Effects Excised sections of hairless mouse skins were placed in a diffusion chamber with liquid baths on both sides. One of the liquid baths was "hot", i.e., it contained radiolabelled C-14 L-glucose.
(Normal sugar is D-glucose, also referred to as dextrose.) The cold, or "sink" side, of the mouse skin was sampled. The data was most consistent with non-specific binding of the L-glucose onto the skin surface. The L-glucose skin binding prevents molecular transfer across the skin. Thus, this control serves to demonstrate one of the problems which this invention is contemplated to overcome.

Example 3: In Vitro Rat Tests:
Two in vitro rat experiments were performed using 1 uCi H-3 mannitol and 10 mM unlabelled mannitol on the hot bath side. Adjacent skin samples were taken from the ra~, using one as the control sample and the other as the test sample.
The test sample was treated with electroporative pulses of 80 V and 4.5 uS duration at 0.5 Hz during hours 4-11 of the experiment. After a six hour lag time, the pulsed skin had 30% greater flux than the control. It should be noted, however, that the -29- l 3262~8 statistical validity of the effect cannot be determined from one experiment.
The permeability of the test sample was about 4xlO 8 cm/sec. This is about 270 times less than 05 the in vivo case, demonstrating the effect of having ` to transfer the mannitol through the whole skin thickness rather than the much shorter distance from the skin surface to the capillary bed.

Example 4: In Vitro Frog Tests:
Two in vitro frog experiments were performed in a similar manner to the rat experiments. Pulsing was 20 V, 100 uS, at 0.24 Hz. Within 1 hour after pulsing, the pulsed skin's permeability increased 4 fold over both its own baseline permeability and that of the control skin. This increased perme-ability was maintained for 12 hours, but damage occurred to the skin and the increase was not reversible in this experiment.

~ Example 5: In Vivo Rat Tests:
Two in vivo experiments using H-3 mannitol were performed on rats. 10 uCi of the H-3 mannitol were painted on skin. Urine was collected and measured.
In the control rat, a constant flux without lag was observed over 36 hours. In the second rat, the skin was pulsed with a 1 Hz square wave of 80 V magnitude and 1 uS duration during hours 28 to 34 of the experiment. This pulse was 2-lOx that required to produce REB in in vitro experiments, but the circuit in vivo was different, and ion permeability could .,, f'"
, '' r~

/

not be measured. Due to sporadic urine output, the ` result appears positive but some ambiguity remains.
The overall permeability of the pulsed skin setup was about 3% of applied dose absorbed per day.

~ 05 Equivalents `, Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiment of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

"
.~
;

Claims (23)

1. A method for transporting molecules across tissue comprising the steps of:
a) applying at least one electrical pulse of sufficient voltage and duration to a region of tissue, wherein the tissue comprise at least a single layer of cells, in order to cause electroporation in the region; and b) utilizing a driving force to move molecules across the regions of the tissue undergoing electroporation.
2. A method of Claim 1, wherein the tissue is selected from the group consisting of animal tissue and plant tissue.
3. A method as in Claim 2, wherein the animal tissue comprises skin.
4. A method as in Claim 3, wherein the skin comprises human skin.
5. A method as in Claim 2, wherein the animal tissue is selected from the group consisting of buccal, vaginal and rectal membrane.
6. A method as in Claim 2, wherein the tissue is artificial tissue.
7. A method as in Claim 2, wherein a high permeability state caused by the electroporation is used to increase and control molecular transport through the walls of sweat ducts or hair follicles.
8. A method as in Claim 1, wherein the driving force is electrical force.
9. A method as in Claim 8, wherein the driving force is iontopheresis.
10. A method as in Claim 1, wherein the driving force is a non-electrical physical or chemical force.
11. A method as in Claim 10, wherein the driving physical force is selected from the group consisting of:
pressure gradients, and concentration gradients.
12. A method as in Claim 1, wherein the transported molecules comprise a pharmaceutical.
13. A method as in Claim 1, wherein the transported molecules comprise a compound of diagnostic interest.
14. A method as in Claim 1, further comprising the step of monitoring the electrical resistance of the tissue in order to determine the occurrence of reversible electrical breakdown.
15. A method as in Claim 14, wherein the measurement of the reversible electrical breakdown is sued to provide an indication of the occurrence of electroporation.
16. A method as in Claim 15, wherein the measurement of reversible electrical breakdown is used to provide an indication of the occurrence of electroporation to a means capable of automatically controlling pulse voltage and duration as well as time between pulses when more than one pulse is applied.
17. A method as in Claim 14, wherein electrical resistance of the tissue is determined from the reversible electrical breakdown measurement, said electrical resistance being used to estimate the change in the permeability of the tissue.
18. A method as in Claim 1, wherein the electrical pulse is of sufficient voltage and duration to produce a permanent, high permeability condition in some cells of the tissue undergoing electroporation.
19. A method as in Claim 18 in which the electrical resistance of the tissue is monitored in order to determine the occurrence of a permanent high permeability condition in some cells of the tissue undergoing electroporation.
20. A method as in Claim 1, wherein the electrical pulse is selected from the group consisting of square wave pulses, saw tooth pulses, triangular wave pulses, exponential wave pulses and sine wave pulses.
21. A method for temporarily increasing the permeability of tissue which comprises applying at least one electrical pulse of sufficient voltage and duration to a region of tissue, wherein the tissue comprises at least a single layer of cells, said method further characterized by the occurrence of reversible electrical breakdown in the electroporated region and wherein the electroporated region is used as a site of molecular transport.
22. A method as in Claim 21, wherein the driving force is used to increase molecular transport at the electroporated region.
23. A method as in Claim 22, wherein the driving force is selected from the group consisting of pressure gradients, concentration gradients, and iontophoresis.
CA000588839A 1988-01-21 1989-01-20 Transport of molecules across tissue using electroporation Expired - Fee Related CA1326268C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14634388A 1988-01-21 1988-01-21
US146,343 1993-11-01

Publications (1)

Publication Number Publication Date
CA1326268C true CA1326268C (en) 1994-01-18

Family

ID=22516946

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000588839A Expired - Fee Related CA1326268C (en) 1988-01-21 1989-01-20 Transport of molecules across tissue using electroporation

Country Status (7)

Country Link
US (1) US5019034B1 (en)
EP (1) EP0398960B1 (en)
JP (1) JP2798459B2 (en)
AT (1) ATE131081T1 (en)
CA (1) CA1326268C (en)
DE (1) DE68925030T2 (en)
WO (1) WO1989006555A1 (en)

Families Citing this family (381)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956032B1 (en) 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
US5547467A (en) * 1988-01-21 1996-08-20 Massachusettes Institute Of Technology Method for rapid temporal control of molecular transport across tissue
US5389069A (en) * 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US4950229A (en) * 1989-09-25 1990-08-21 Becton, Dickinson And Company Apparatus for an electrode used for iontophoresis
EP0497919B1 (en) * 1989-10-23 1996-12-11 THERATECH, INC. (a Delaware Corporation) Iontophoresis device using a rate-controlling membrane
DE4028125A1 (en) * 1990-01-17 1991-07-18 Klimke Markus Application plaster for regulated dosing of various pharmacons - uses electrical correct for percutaneous transport for local and systematic therapy
CH687002A5 (en) * 1990-04-04 1996-08-30 Isabella Koester Low current medical stimulation device
US5094594A (en) * 1990-04-23 1992-03-10 Genomyx, Incorporated Piezoelectric pumping device
US5236413B1 (en) * 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
CA2042093C (en) * 1990-05-09 2002-12-24 Gyula Hadlaczky Cell line carrying an excess of mammalian centromeres
CA2019758C (en) * 1990-06-25 2001-09-04 Kevin L. Firth Improved electroporation device and method
US6139537A (en) * 1990-11-01 2000-10-31 Tapper; Robert Iontophoretic treatment system
US6235013B1 (en) 1990-11-01 2001-05-22 Robert Tapper Iontophoretic treatment system
US6223076B1 (en) 1990-11-01 2001-04-24 Robert Tapper Sweat control system
US6575957B1 (en) * 1990-11-01 2003-06-10 Robert Tapper Iontophoretic treatment system
US6582416B2 (en) 1990-11-01 2003-06-24 Robert Tapper Iontophoretic treatment system
US5224927A (en) * 1990-11-01 1993-07-06 Robert Tapper Iontophoretic treatment system
US6600950B1 (en) * 1990-11-01 2003-07-29 Robert Tapper Iontophoretic treatment system
US6238381B1 (en) 1990-11-01 2001-05-29 Robert Tapper Iontophoretic treatment system
US5431625A (en) * 1991-02-01 1995-07-11 Empi, Inc. Iontophoresis electronic device having a ramped output current
US5131403A (en) * 1991-06-05 1992-07-21 Becton Dickinson And Company Method for obtaining blood using iontophoresis
US6132419A (en) * 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5501662A (en) * 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
DE4217039C2 (en) * 1992-05-22 1995-07-13 Boehringer Ingelheim Kg Device for iontophoretic application, in which the active substance flow is maximized, device for determining the associated frequency and corresponding iontophoresis method
US5318514A (en) * 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
US6009345A (en) * 1992-08-17 1999-12-28 Genetronics, Inc. Method and apparatus for a combination of electroporation and iontophoresis for the delivery of drugs and genes
US5462520A (en) * 1992-08-17 1995-10-31 Genetronics, Inc. Transsurface drug delivery by electrofusion of microbubbles to the tissue surface
US5464386A (en) * 1992-08-17 1995-11-07 Genetronics, Inc. Transdermal drug delivery by electroincorporation of vesicles
US5688233A (en) * 1992-08-17 1997-11-18 Genetronics, Inc. Electronincorporation enhanced transdermal delivery of molecules
US5421816A (en) * 1992-10-14 1995-06-06 Endodermic Medical Technologies Company Ultrasonic transdermal drug delivery system
US5468223A (en) * 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5439440A (en) * 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5885211A (en) * 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
IL108775A (en) * 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
RU2204608C2 (en) * 1994-06-09 2003-05-20 Инноженетик Н.В. Method of detection of mycobacterium resistance to rifampicin with their possible identification, method of hybridization, probe and composition for its realization, set of primers (variants)
IE960375A1 (en) * 1995-06-05 1996-12-11 Alza Corp Device for transdermal electrotransport delivery of fentanyl¹and sufentanil
US6425892B2 (en) * 1995-06-05 2002-07-30 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6216033B1 (en) * 1996-05-22 2001-04-10 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
PT836511E (en) * 1995-06-05 2004-08-31 Alza Corp DEVICE FOR DISTRIBUTION OF FENTANIL AND SUFENTANIL BY PERCUTANEOUS ELECTROTRANSPORTS
US5983130A (en) 1995-06-07 1999-11-09 Alza Corporation Electrotransport agent delivery method and apparatus
US6041252A (en) * 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US7572252B1 (en) 1995-06-07 2009-08-11 Alza Corporation Electrotransport agent delivery method and apparatus
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
US5983131A (en) * 1995-08-11 1999-11-09 Massachusetts Institute Of Technology Apparatus and method for electroporation of tissue
EP2921111A1 (en) * 1995-08-29 2015-09-23 Nitto Denko Corporation Microporation of human skin for drug delivery and monitoring applications
TR199800347T1 (en) * 1995-08-29 1998-05-21 Spectrx, Inc. Micro-poring of human skin for drug application and monitoring applications.
US5833647A (en) * 1995-10-10 1998-11-10 The Penn State Research Foundation Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery
US6010613A (en) * 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US5988169A (en) * 1996-03-29 1999-11-23 Iotek, Inc. Vaginal insert and method for treating urogenital disorders
US6030375A (en) * 1996-03-29 2000-02-29 Iotek, Inc. Compressible vaginal insert and method for treating urogenital disorders
US6077697A (en) 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6718201B1 (en) * 1996-06-07 2004-04-06 Alza Corporation Electrotransport agent delivery method and apparatus
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
DE69736862T2 (en) * 1996-07-17 2007-05-31 Medtronic, Inc., Minneapolis Delivery system for delivery of genetic material to cardiac tissue
US5911223A (en) * 1996-08-09 1999-06-15 Massachusetts Institute Of Technology Introduction of modifying agents into skin by electroporation
FR2755842B1 (en) * 1996-11-19 1999-04-23 Lhd Lab Hygiene Dietetique METHOD FOR MEASURING THE SKIN RESISTANCE OF A PATIENT SUBJECT TO A TRANSDERMAL ADMINISTRATION OF MEDICAMENT
US6527716B1 (en) 1997-12-30 2003-03-04 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
DK1314400T3 (en) * 1996-12-31 2007-10-15 Altea Therapeutics Corp Microporation of tissues for delivery of bioactive agents
US5810801A (en) * 1997-02-05 1998-09-22 Candela Corporation Method and apparatus for treating wrinkles in skin using radiation
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5873849A (en) * 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6085115A (en) * 1997-05-22 2000-07-04 Massachusetts Institite Of Technology Biopotential measurement including electroporation of tissue surface
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
CN1261808A (en) 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
TW368420B (en) * 1997-11-04 1999-09-01 Genetronics Inc Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum
AU741399B2 (en) * 1997-11-04 2001-11-29 Genetronics, Inc. Combined electroporation and iontophoresis apparatus for drug and gene delivery
US6775569B2 (en) 1997-11-05 2004-08-10 Hisamitsu Pharmaceutical Co., Inc. Electroporation device for in vivo delivery of therapeutic agents
SE9704076D0 (en) * 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilization of cell structures and use thereof
US6295469B1 (en) * 1997-11-14 2001-09-25 Alza Corporation Formulation for electrically assisted delivery of lidocaine and epinephrine
US8287483B2 (en) * 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US7066884B2 (en) 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
WO2000035357A1 (en) * 1998-12-18 2000-06-22 Sontra Medical, Inc. Methods and apparatus for enhancement of transdermal transport
US20060015058A1 (en) * 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
US6059736A (en) * 1998-02-24 2000-05-09 Tapper; Robert Sensor controlled analysis and therapeutic delivery system
AU733053C (en) 1998-02-24 2001-11-29 Boston Scientific Limited High flow rate dialysis catheters and related methods
US6022316A (en) * 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications
US6173202B1 (en) 1998-03-06 2001-01-09 Spectrx, Inc. Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
SE513814C2 (en) * 1998-03-31 2000-11-06 Aditus Medical Ab Device for the treatment of diseases with electric fields
AU3973599A (en) 1998-05-08 1999-11-29 Genetronics, Inc. Electrically induced vessel vasodilation
WO1999058190A1 (en) * 1998-05-13 1999-11-18 Cygnus, Inc. Collection assemblies for transdermal sampling system
US6027488A (en) 1998-06-03 2000-02-22 Genetronics, Inc. Flow-through electroporation system for ex vivo gene therapy
US20040229363A1 (en) * 1998-06-24 2004-11-18 Ed Nolan High efficiency transfection based on low electric field strength, long pulse length
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
DE69936866T2 (en) * 1998-06-26 2008-04-30 Genetronics, Inc., San Diego SYNERGISM OF PHOTODYNAMIC AND ELECTROPERMEATION EFFECTS ON CELL VITALITY AS A NEW CYTOTOXIC AGENT
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US6302874B1 (en) * 1998-07-13 2001-10-16 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
CA2337652C (en) 1998-07-13 2013-03-26 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6532386B2 (en) 1998-08-31 2003-03-11 Johnson & Johnson Consumer Companies, Inc. Electrotransort device comprising blades
US6148231A (en) * 1998-09-15 2000-11-14 Biophoretic Therapeutic Systems, Llc Iontophoretic drug delivery electrodes and method
US6150148A (en) * 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US6219575B1 (en) * 1998-10-23 2001-04-17 Babak Nemati Method and apparatus to enhance optical transparency of biological tissues
US20130274837A1 (en) * 1998-10-23 2013-10-17 Babak Nemati Systems and Methods to Enhance Optical Transparency of Biological Tissues for Photobiomodulation
US6708060B1 (en) 1998-11-09 2004-03-16 Transpharma Ltd. Handheld apparatus and method for transdermal drug delivery and analyte extraction
US6597946B2 (en) 1998-11-09 2003-07-22 Transpharma Ltd. Electronic card for transdermal drug delivery and analyte extraction
US6148232A (en) 1998-11-09 2000-11-14 Elecsys Ltd. Transdermal drug delivery and analyte extraction
US6611706B2 (en) 1998-11-09 2003-08-26 Transpharma Ltd. Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US5983135A (en) * 1998-12-24 1999-11-09 Avrahami; Zohar Transdermal delivery of fine powders
US6183773B1 (en) * 1999-01-04 2001-02-06 The General Hospital Corporation Targeting of sebaceous follicles as a treatment of sebaceous gland disorders
DE60007290T2 (en) 1999-01-28 2004-09-23 Cyto Pulse Sciences, Inc. INTRODUCTION OF MACROMOLECULES IN CELLS
US6317630B1 (en) 1999-01-29 2001-11-13 Yossi Gross Drug delivery device
AU765788B2 (en) 1999-02-10 2003-10-02 Gmp Drug Delivery, Inc. Iontophoresis, electroporation and combination patches for local drug delivery
US7127285B2 (en) * 1999-03-12 2006-10-24 Transport Pharmaceuticals Inc. Systems and methods for electrokinetic delivery of a substance
US6792306B2 (en) * 2000-03-10 2004-09-14 Biophoretic Therapeutic Systems, Llc Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US6553253B1 (en) * 1999-03-12 2003-04-22 Biophoretic Therapeutic Systems, Llc Method and system for electrokinetic delivery of a substance
US6678558B1 (en) * 1999-03-25 2004-01-13 Genetronics, Inc. Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
US6627421B1 (en) * 1999-04-13 2003-09-30 Imarx Therapeutics, Inc. Methods and systems for applying multi-mode energy to biological samples
ATE290902T1 (en) 1999-04-16 2005-04-15 Johnson & Johnson Consumer DEVICE FOR IONTOPHORETIC ADMINISTRATION OF MEDICATION WITH INTERNAL SENSORS
US7171264B1 (en) * 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US6520950B1 (en) 1999-05-10 2003-02-18 Genetronics, Inc. Method of electroporation-enhanced delivery of active agents
WO2000078207A2 (en) * 1999-06-22 2000-12-28 The Secretary Of State For Defence Analyte detection
CA2377565A1 (en) * 1999-06-25 2001-01-04 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
AU2006200389B2 (en) * 1999-06-25 2008-04-24 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
US6300108B1 (en) * 1999-07-21 2001-10-09 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6326177B1 (en) 1999-08-04 2001-12-04 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Method and apparatus for intracellular electro-manipulation
US20030078499A1 (en) * 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
US7133717B2 (en) 1999-08-25 2006-11-07 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery and diagnostic sampling
US7113821B1 (en) * 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
WO2001026690A1 (en) * 1999-10-13 2001-04-19 Pola Chemical Industries Inc. Percutaneous permeability-controlling agents and compositions for electroporation containing the same
WO2001026687A1 (en) * 1999-10-14 2001-04-19 Pola Chemical Industries Inc. Compositions for electroporation
AU3671900A (en) 1999-10-14 2001-04-23 Pola Chemical Industries Inc. Compositions for electroporation
DE60028593T2 (en) * 1999-10-15 2007-01-25 Pola Chemical Industries, Inc. PERCUTANEAN ABSORPTION ACCELERATOR FOR ELECTROPORATION
US6868289B2 (en) * 2002-10-02 2005-03-15 Standen Ltd. Apparatus for treating a tumor or the like and articles incorporating the apparatus for treatment of the tumor
WO2001060448A1 (en) 2000-02-18 2001-08-23 University Of Utah Research Foundation Methods for extracting substances using alternating current
CA2400325A1 (en) 2000-02-18 2001-08-23 University Of Utah Research Foundation Methods for delivering agents using alternating current
US6714816B1 (en) * 2000-02-22 2004-03-30 University Of South Florida Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo
AU2001250859A1 (en) * 2000-03-16 2001-09-24 Joseph J. Drabick Method for gene transfection and vaccination through skin using electropermeabilization
IT1320187B1 (en) * 2000-04-21 2003-11-26 Igea Srl ELECTRO-PORTATION DEVICE AND METHOD THAT PROVIDES A MODULATED SIGNAL UNDER THE CONTINUOUS CONTROL OF THE ELECTRO-PERMEABILIZATION
IL136008A0 (en) * 2000-05-07 2001-05-20 Elecsys Ltd Electrically-mediated transdermal drug injection
US6706032B2 (en) 2000-06-08 2004-03-16 Massachusetts Institute Of Technology Localized molecular and ionic transport to and from tissues
US7597692B2 (en) * 2000-06-08 2009-10-06 Massachusetts Institute Of Technology Microscission processes and procedures
EP1313448B1 (en) * 2000-08-16 2010-04-07 The General Hospital Corporation doing business as Massachusetts General Hospital Topical aminolevulinic acid-photodynamic therapy for acne vulgaris
US8251986B2 (en) * 2000-08-17 2012-08-28 Angiodynamics, Inc. Method of destroying tissue cells by eletroporation
US6892099B2 (en) * 2001-02-08 2005-05-10 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US6697670B2 (en) 2001-08-17 2004-02-24 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US6795728B2 (en) 2001-08-17 2004-09-21 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation
DE60141760D1 (en) * 2000-09-28 2010-05-20 Bioriginal Food & Science Corp FAD4, FAD5, FAD5-2, AND FAD6, MEMBERS OF THE FATTY ACID FAMILY FAMILY AND ITS USES
US6553255B1 (en) 2000-10-27 2003-04-22 Aciont Inc. Use of background electrolytes to minimize flux variability during iontophoresis
US7137975B2 (en) * 2001-02-13 2006-11-21 Aciont, Inc. Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
EP1369108A4 (en) * 2001-02-19 2007-06-20 Pola Chem Ind Inc Composition for use in electroporation
DE20109614U1 (en) 2001-03-05 2001-09-06 Zimmermann Johann Electrode for the collection of body fluids and the administration of active substances / drugs through the skin, transdermally without penetrating the skin, and this in humans and animals
BR0116990A (en) * 2001-04-27 2004-03-02 Biophoretic Therapeutics Syste Method and system for electrokinetic release of a substance
WO2003039620A2 (en) 2001-05-17 2003-05-15 Transpharma Medical Ltd. Integrated transdermal drug delivery system
US6733485B1 (en) 2001-05-25 2004-05-11 Advanced Bionics Corporation Microstimulator-based electrochemotherapy methods and systems
CA2448096A1 (en) * 2001-05-30 2002-12-05 Chromos Molecular Systems, Inc. Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
US20030065285A1 (en) * 2001-07-23 2003-04-03 Higuchi William I. Method and apparatus for increasing flux during reverse iontophoresis
US7130697B2 (en) * 2002-08-13 2006-10-31 Minnesota Medical Physics Llc Apparatus and method for the treatment of benign prostatic hyperplasia
US6994706B2 (en) 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
USRE42016E1 (en) 2001-08-13 2010-12-28 Angiodynamics, Inc. Apparatus and method for the treatment of benign prostatic hyperplasia
DE60217393T2 (en) * 2001-11-27 2007-10-18 Cellectricon Ab METHOD FOR THE COMBINED PARALLEL INTRODUCTION OF AGENTS AND ELECTROPORATION FOR CELL STRUCTURES AND USE THEREOF
WO2003047684A2 (en) * 2001-12-04 2003-06-12 University Of Southern California Method for intracellular modifications within living cells using pulsed electric fields
US20040219660A1 (en) * 2001-12-14 2004-11-04 Dev Sukhendu B. Electroporation-mediated intravascular delivery
EP1484084A4 (en) 2002-01-24 2009-12-23 Hisamitsu Pharmaceutical Co Electrode structure
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US8116860B2 (en) * 2002-03-11 2012-02-14 Altea Therapeutics Corporation Transdermal porator and patch system and method for using same
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
CA2478822C (en) 2002-03-11 2016-07-12 Altea Therapeutics Corporation Transdermal drug delivery patch system, method of making same and method of using same
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8150520B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods for catheter-based renal denervation
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US8131371B2 (en) * 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
EP1499255B1 (en) * 2002-04-19 2015-07-22 Syneron Medical Ltd. Handheld transdermal drug delivery and analyte extraction
US20040082859A1 (en) 2002-07-01 2004-04-29 Alan Schaer Method and apparatus employing ultrasound energy to treat body sphincters
JP2004081712A (en) 2002-08-29 2004-03-18 Kyodo Printing Co Ltd Electrode arrangement
WO2004028379A1 (en) * 2002-09-25 2004-04-08 Flock, Stephen, T. Microsurgical tissue treatment system
US20040236269A1 (en) * 2002-09-25 2004-11-25 Marchitto Kevin S. Microsurgical tissue treatment system
US7383084B2 (en) * 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US8133505B2 (en) * 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd Transdermal delivery system for water insoluble drugs
IL152574A (en) * 2002-10-31 2009-09-22 Transpharma Medical Ltd Transdermal delivery system for dried particulate or lyophilized medications
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd Transdermal delivery system for anti-emetic medication
US7662404B2 (en) * 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
CA2552690C (en) * 2002-12-31 2014-12-09 Ultra-Sonic Technologies, L.L.C. Transdermal delivery using encapsulated agent activated by ultrasound and/or heat
US20040267240A1 (en) * 2003-01-29 2004-12-30 Yossi Gross Active drug delivery in the gastrointestinal tract
US20050058701A1 (en) * 2003-01-29 2005-03-17 Yossi Gross Active drug delivery in the gastrointestinal tract
KR20050098277A (en) * 2003-01-29 2005-10-11 이-필 파마 리미티드 Active drug delivery in the gastrointestinal tract
TW200416015A (en) * 2003-02-17 2004-09-01 Wei-Gung Wang Device for selectively generating hydrogen ions in an aqueous solution
US20060254912A1 (en) * 2003-03-04 2006-11-16 Amos Nussinovitch System and method for treating biological tissue usiing curret electrical field
US20050177201A1 (en) * 2003-03-31 2005-08-11 Freeman Gary A. Probe insertion pain reduction method and device
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US8455228B2 (en) * 2003-07-16 2013-06-04 University Of South Florida Method to facilitate directed delivery and electroporation using a charged stream
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
KR20070011240A (en) * 2003-11-13 2007-01-24 알자 코포레이션 System and method for transdermal delivery
US8298222B2 (en) 2003-12-24 2012-10-30 The Regents Of The University Of California Electroporation to deliver chemotherapeutics and enhance tumor regression
JP5138229B2 (en) * 2003-12-24 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Tissue ablation by irreversible electroporation
JP4879754B2 (en) * 2004-01-22 2012-02-22 リハブトロニクス インコーポレーテッド Method for carrying electrical current to body tissue via implanted non-active conductor
WO2005084275A2 (en) 2004-02-27 2005-09-15 Iomed, Inc. Iontophoretic electrode
US20050209548A1 (en) * 2004-03-19 2005-09-22 Dev Sukhendu B Electroporation-mediated intravascular delivery
JP4443278B2 (en) * 2004-03-26 2010-03-31 テルモ株式会社 Catheter with expansion body
US20060100567A1 (en) * 2004-07-30 2006-05-11 Rocky Mountain Biosystems, Inc Microsurgical tissue treatment system
US20060094945A1 (en) * 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis
WO2006063063A2 (en) * 2004-12-09 2006-06-15 Flexible Medical Systems, Llc Apparatus and method for continuous real-time trace biomolecular sampling, analysis and delivery
US8277495B2 (en) * 2005-01-13 2012-10-02 Candela Corporation Method and apparatus for treating a diseased nail
US7850645B2 (en) * 2005-02-11 2010-12-14 Boston Scientific Scimed, Inc. Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power
US8101169B2 (en) * 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US7923251B2 (en) * 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
US7601149B2 (en) 2005-03-07 2009-10-13 Boston Scientific Scimed, Inc. Apparatus for switching nominal and attenuated power between ablation probes
US7704743B2 (en) * 2005-03-30 2010-04-27 Georgia Tech Research Corporation Electrosonic cell manipulation device and method of use thereof
US20060240084A1 (en) * 2005-04-20 2006-10-26 Xylos Corporation Microbial cellulose materials for use in transdermal drug delivery systems, method of manufacture and use
US20060264752A1 (en) * 2005-04-27 2006-11-23 The Regents Of The University Of California Electroporation controlled with real time imaging
JP2008540023A (en) * 2005-05-19 2008-11-20 イー−ピル ファーマ リミティド Ingestible device for nitric oxide production in tissues
US20060293730A1 (en) 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating restenosis sites using electroporation
US20060293725A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating fatty tissue sites using electroporation
US8114070B2 (en) * 2005-06-24 2012-02-14 Angiodynamics, Inc. Methods and systems for treating BPH using electroporation
US20060293731A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating tumors using electroporation
US8214221B2 (en) * 2005-06-30 2012-07-03 Lg Electronics Inc. Method and apparatus for decoding an audio signal and identifying information included in the audio signal
US20070176262A1 (en) * 2005-08-11 2007-08-02 Ernest Sirkin Series connection of a diode laser bar
US20070173799A1 (en) * 2005-09-01 2007-07-26 Hsia James C Treatment of fatty tissue adjacent an eye
WO2007038567A1 (en) * 2005-09-28 2007-04-05 Candela Corporation Treating cellulite
US20070083190A1 (en) * 2005-10-11 2007-04-12 Yacov Domankevitz Compression device for a laser handpiece
EP1956985A2 (en) * 2005-11-23 2008-08-20 Universität Zürich Allergy treatment by epicutaneous allergen administration
US7432069B2 (en) * 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
US8333874B2 (en) * 2005-12-09 2012-12-18 Flexible Medical Systems, Llc Flexible apparatus and method for monitoring and delivery
JP4961137B2 (en) * 2005-12-14 2012-06-27 久光製薬株式会社 Device for iontophoresis
US7891362B2 (en) * 2005-12-23 2011-02-22 Candela Corporation Methods for treating pigmentary and vascular abnormalities in a dermal region
US20070156135A1 (en) * 2006-01-03 2007-07-05 Boris Rubinsky System and methods for treating atrial fibrillation using electroporation
US20080045880A1 (en) * 2006-02-11 2008-02-21 Rune Kjeken Device and method for single-needle in vivo electroporation
US20080287857A1 (en) * 2006-02-11 2008-11-20 Rune Kjeken Device and method for single-needle in vivo electroporation
AU2007215263B2 (en) 2006-02-11 2011-07-07 Genetronics, Inc. Device and method for single-needle in vivo electroporation
DE102006009157B4 (en) * 2006-02-24 2015-08-20 Eisenmann Ag Method for digesting biological material and device for its implementation
US7709631B2 (en) 2006-03-13 2010-05-04 Xylos Corporation Oxidized microbial cellulose and use thereof
WO2007116959A1 (en) 2006-04-07 2007-10-18 Hisamitsu Pharmaceutical Co., Inc. Microneedle device and transdermal administration device provided with microneedles
US20070286884A1 (en) * 2006-06-13 2007-12-13 Xylos Corporation Implantable microbial cellulose materials for hard tissue repair and regeneration
US8246611B2 (en) * 2006-06-14 2012-08-21 Candela Corporation Treatment of skin by spatial modulation of thermal heating
US7996077B2 (en) * 2006-09-06 2011-08-09 Encore Medical Asset Corporation Iontophoresis apparatus and method
US8214030B2 (en) 2006-09-06 2012-07-03 Encore Medical Asset Corporation Iontophoresis apparatus and method
EP2076313A4 (en) * 2006-10-16 2012-07-25 Univ California Gels with predetermined conductivity used in irreversible electroporation of tissue
KR101421760B1 (en) * 2006-10-17 2014-07-22 브이지엑스 파머시우티컬즈, 인크. Electroporation devices and methods of using same for electroporation of cells in mammals
US20080132884A1 (en) * 2006-12-01 2008-06-05 Boris Rubinsky Systems for treating tissue sites using electroporation
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
US8812071B2 (en) * 2007-03-07 2014-08-19 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
US20080221649A1 (en) * 2007-03-09 2008-09-11 Agustina Echague Method of sequentially treating tissue
US20100210932A1 (en) * 2007-03-20 2010-08-19 Bayer Healthcare Llc Method of analyzing an analyte
US8386027B2 (en) * 2007-04-27 2013-02-26 Echo Therapeutics, Inc. Skin permeation device for analyte sensing or transdermal drug delivery
CA2724949A1 (en) * 2007-06-27 2008-12-31 The General Hospital Corporation Method and apparatus for optical inhibition of photodynamic therapy
WO2009050718A2 (en) 2007-10-17 2009-04-23 Transpharma Medical Ltd. Dissolution rate verification
US20090247933A1 (en) 2008-03-27 2009-10-01 The Regents Of The University Of California; Angiodynamics, Inc. Balloon catheter method for reducing restenosis via irreversible electroporation
US20100004623A1 (en) * 2008-03-27 2010-01-07 Angiodynamics, Inc. Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation
US10448989B2 (en) 2009-04-09 2019-10-22 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
AU2009243079A1 (en) 2008-04-29 2009-11-05 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
US8992517B2 (en) 2008-04-29 2015-03-31 Virginia Tech Intellectual Properties Inc. Irreversible electroporation to treat aberrant cell masses
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US9198733B2 (en) 2008-04-29 2015-12-01 Virginia Tech Intellectual Properties, Inc. Treatment planning for electroporation-based therapies
US9283051B2 (en) 2008-04-29 2016-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US8348938B2 (en) * 2008-05-06 2013-01-08 Old Dominian University Research Foundation Apparatus, systems and methods for treating a human tissue condition
WO2009137800A2 (en) 2008-05-09 2009-11-12 Angiodynamics, Inc. Electroporation device and method
WO2009155526A2 (en) * 2008-06-20 2009-12-23 Angiodynamics, Inc. Device and method for the ablation of fibrin sheath formation on a venous catheter
WO2010008834A2 (en) * 2008-06-23 2010-01-21 Angiodynamics, Inc. Treatment devices and methods
DE102008032829A1 (en) 2008-07-03 2010-02-04 Technische Universität Dresden Promoting and regulating biotechnological processes, comprises introducing polar crystals in form of nanoparticles and applying crystals into contact with biological material, stimulating crystals and promoting enzyme production process
US20100152725A1 (en) * 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
WO2010080886A1 (en) 2009-01-09 2010-07-15 Recor Medical, Inc. Methods and apparatus for treatment of mitral valve in insufficiency
WO2010085765A2 (en) * 2009-01-23 2010-07-29 Moshe Meir H Therapeutic energy delivery device with rotational mechanism
WO2010093692A2 (en) * 2009-02-10 2010-08-19 Hobbs Eamonn P Irreversible electroporation and tissue regeneration
US8606366B2 (en) 2009-02-18 2013-12-10 Syneron Medical Ltd. Skin treatment apparatus for personal use and method for using same
CA2655017A1 (en) * 2009-02-20 2010-08-20 Abdeltif Essalik Non-invasive biomedical detection and monitoring systems
WO2010118387A1 (en) * 2009-04-09 2010-10-14 Virginia Tech Intellectual Properties, Inc. Integration of very short electric pulses for minimally to noninvasive electroporation
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
US20110066175A1 (en) * 2009-05-07 2011-03-17 Rainbow Medical Ltd. Gastric anchor
US20100286587A1 (en) * 2009-05-07 2010-11-11 Yossi Gross Sublingual electrical drug delivery
US20100286628A1 (en) * 2009-05-07 2010-11-11 Rainbow Medical Ltd Gastric anchor
US8414559B2 (en) * 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
WO2010129899A1 (en) * 2009-05-08 2010-11-11 Cellutions, Inc. Treatment system with a pulse forming network for achieving plasma in tissue
USD630321S1 (en) 2009-05-08 2011-01-04 Angio Dynamics, Inc. Probe handle
BRPI1011316B8 (en) 2009-05-26 2021-06-22 Massachusetts Gen Hospital apparatus for administering a substance to skin tissue
US8903488B2 (en) 2009-05-28 2014-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US20110118732A1 (en) 2009-11-19 2011-05-19 The Regents Of The University Of California Controlled irreversible electroporation
US20110190745A1 (en) * 2009-12-04 2011-08-04 Uebelhoer Nathan S Treatment of sweat glands
WO2011100376A2 (en) 2010-02-10 2011-08-18 Incube Labs, Llc Methods and architecture for power optimization of iontophoretic transdermal drug delivery
KR102593818B1 (en) * 2010-04-28 2023-10-25 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
US9700368B2 (en) 2010-10-13 2017-07-11 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
EP3449856B1 (en) 2010-10-25 2023-06-28 Medtronic Ardian Luxembourg S.à.r.l. Device for evaluation and feedback of neuromodulation treatment
US9877673B2 (en) 2010-12-10 2018-01-30 Clinitech, Llc Transdermal sampling and analysis device
US9451913B2 (en) 2010-12-10 2016-09-27 Touchtek Labs, Llc Transdermal sampling and analysis device
US8428708B1 (en) 2012-05-21 2013-04-23 Incline Therapeutics, Inc. Self-test for analgesic product
US8781571B2 (en) 2011-03-31 2014-07-15 Incline Therapeutics, Inc. Switch validation circuit and method
US8428709B1 (en) 2012-06-11 2013-04-23 Incline Therapeutics, Inc. Current control for electrotransport drug delivery
US9731121B2 (en) 2011-03-31 2017-08-15 Incline Therapeutics, Inc. Switch validation circuit and method
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
US9968284B2 (en) 2011-12-02 2018-05-15 Clinitech, Llc Anti-interferent barrier layers for non-invasive transdermal sampling and analysis device
EP2790684B1 (en) 2011-12-16 2016-10-12 3M Innovative Properties Company Foldable adhesive composite dressing
US9414881B2 (en) 2012-02-08 2016-08-16 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
US9750568B2 (en) 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
WO2013134733A2 (en) 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg Sarl Biomarker sampling in the context of neuromodulation devices and associated systems and methods
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
US10166321B2 (en) 2014-01-09 2019-01-01 Angiodynamics, Inc. High-flow port and infusion needle systems
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
RU2699278C2 (en) * 2014-05-02 2019-09-04 Конинклейке Филипс Н.В. Bacterial inactivation device
US10471254B2 (en) 2014-05-12 2019-11-12 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
GB201415611D0 (en) * 2014-09-03 2014-10-15 Univ Strathclyde Apparatus for topical application of material
WO2016100325A1 (en) 2014-12-15 2016-06-23 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
CN114209420A (en) 2015-10-07 2022-03-22 梅约医学教育与研究基金会 Electroporation for the treatment of obesity or diabetes
WO2017123954A1 (en) * 2016-01-15 2017-07-20 University Of Cincinnati Advanced electroporation devices and methods for analyte access in biofluids
JP7158820B2 (en) 2016-10-26 2022-10-24 ロレアル Electroporation device and method for controlling electroporation device
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
US11045648B2 (en) 2017-11-14 2021-06-29 Boston Scientific Scimed, Inc. Irreversible electroporation through a combination of substance injection and electrical field application
JP2021503281A (en) 2017-11-17 2021-02-12 アイオバンス バイオセラピューティクス,インコーポレイテッド TIL expansion culture from fine needle suction and small biopsy
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US11364070B2 (en) 2018-01-23 2022-06-21 Boston Scientific Scimed, Inc. Enhanced needle array and therapies for tumor ablation
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
MX2021004953A (en) 2018-11-05 2021-08-11 Iovance Biotherapeutics Inc Selection of improved tumor reactive t-cells.
BR112021008549A2 (en) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Method of treating non-small cell lung cancer with a population of tumor-infiltrating lymphocytes
JOP20210094A1 (en) 2018-11-05 2023-01-30 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
CN113748202A (en) 2019-03-01 2021-12-03 艾欧凡斯生物治疗公司 Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US11633129B2 (en) 2019-04-05 2023-04-25 Cambridge Medical Technologies LLC Non-invasive transdermal sampling and analysis device incorporating redox cofactors
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
US11375931B2 (en) 2019-08-08 2022-07-05 Cambridge Medical Technologies LLC Non-invasive transdermal sampling and analysis device incorporating an electrochemical bioassay
US11931094B2 (en) 2019-10-15 2024-03-19 Boston Scientific Scimed, Inc. Control system and user interface for an ablation system
US20220378693A1 (en) * 2019-10-24 2022-12-01 Kiffik Inc. Continuous or periodical transdermal delivery of exogenous molecule
WO2021081378A1 (en) 2019-10-25 2021-04-29 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2023506734A (en) 2019-12-11 2023-02-20 アイオバンス バイオセラピューティクス,インコーポレイテッド Process for the production of tumor-infiltrating lymphocytes (TIL) and methods of using same
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
EP4284919A1 (en) 2021-01-29 2023-12-06 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4308691A1 (en) 2021-03-19 2024-01-24 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
JP2024511414A (en) 2021-03-23 2024-03-13 アイオバンス バイオセラピューティクス,インコーポレイテッド CISH gene editing of tumor-infiltrating lymphocytes and its use in immunotherapy
IL307800A (en) 2021-04-19 2023-12-01 Iovance Biotherapeutics Inc Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CA3219148A1 (en) 2021-05-17 2022-11-24 Frederick G. Vogt Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2023004074A2 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
TW202327631A (en) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3231018A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
US20230187042A1 (en) 2021-10-27 2023-06-15 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024055017A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1481480A (en) * 1974-02-02 1977-07-27 Kernforschungsanlage Juelich Process and apparatus for increasing the permeability of the membrane of cells of organisms
DE2828232C2 (en) * 1978-06-28 1986-04-17 Kernforschungsanlage Jülich GmbH, 5170 Jülich Device for determining the dielectric breakthrough and the size of particles having a membrane as an envelope
US4301794A (en) * 1978-10-18 1981-11-24 Robert Tapper Method for iontophoretic treatment
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
JPS5810066A (en) * 1981-07-10 1983-01-20 株式会社アドバンス Plaster structure for ion tofuorese
US4639244A (en) * 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
DE3317415A1 (en) * 1983-05-13 1984-11-15 Kernforschungsanlage Jülich GmbH, 5170 Jülich CHAMBER FOR TREATING CELLS IN THE ELECTRICAL FIELD
US4622031A (en) * 1983-08-18 1986-11-11 Drug Delivery Systems Inc. Indicator for electrophoretic transcutaneous drug delivery device
US4557723A (en) * 1983-08-18 1985-12-10 Drug Delivery Systems Inc. Applicator for the non-invasive transcutaneous delivery of medicament
US4663292A (en) * 1984-12-21 1987-05-05 Wong Daniel T High-voltage biological macromolecule transfer and cell fusion system
US4702732A (en) * 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
JPS62165991A (en) * 1986-01-17 1987-07-22 Rohm Co Ltd Semiconductor laser element inspecting apparatus
US4786277A (en) * 1986-11-21 1988-11-22 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation
US4822470A (en) * 1987-10-09 1989-04-18 Baylor College Of Medicine Method of and apparatus for cell poration and cell fusion using radiofrequency electrical pulses

Also Published As

Publication number Publication date
DE68925030D1 (en) 1996-01-18
JPH03502416A (en) 1991-06-06
JP2798459B2 (en) 1998-09-17
US5019034A (en) 1991-05-28
WO1989006555A1 (en) 1989-07-27
EP0398960B1 (en) 1995-12-06
DE68925030T2 (en) 1996-07-25
ATE131081T1 (en) 1995-12-15
US5019034B1 (en) 1995-08-15
EP0398960A1 (en) 1990-11-28

Similar Documents

Publication Publication Date Title
CA1326268C (en) Transport of molecules across tissue using electroporation
US5547467A (en) Method for rapid temporal control of molecular transport across tissue
Banga et al. Iontophoresis and electroporation: comparisons and contrasts
JP4394444B2 (en) Devices and methods for controlled intradermal delivery of active agents
Banga Electrically assisted transdermal and topical drug delivery
US6512950B2 (en) Methods for delivering agents using alternating current
Prausnitz A practical assessment of transdermal drug delivery by skin electroporation
Dhote et al. Iontophoresis: a potential emergence of a transdermal drug delivery system
Sintov et al. Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs
Prausnitz The effects of electric current applied to skin: a review for transdermal drug delivery
US6041253A (en) Effect of electric field and ultrasound for transdermal drug delivery
DE69921489T2 (en) ELECTRIC TRANSPORT DEVICE WITH BLADE
JP4216073B2 (en) Tissue electroporation for improved drug delivery and diagnostic sampling
Nanda et al. Current developments using emerging transdermal technologies in physical enhancement methods.
US20030233085A1 (en) Optimization of transcutaneous active permeation of compounds through the synergistic use of ultrasonically generated mechanical abrasion of the skin, chemical enhancers and simultaneous application of sonophoresis, iontophoresis, electroporation, mechanical vibrations and magnetophoresis through single application devices
AU2002363106A1 (en) Device and method for controlled delivery of active substance into the skin
CA2612866A1 (en) Permeabilization of biological membranes
Krueger et al. Iontophoresis: principles and applications
Nikam et al. Iontophoresis in drug delivery: history and application
Hadgraft et al. Biotechnological aspects of transport across human skin
Herwadkar Formulation Optimization And Delivery Enhancement Of Drugs Into And Across Skin And Their Safe Disposal.
Siddoju Topical Iontophoretic Delivery Of Acyclovir.
Costello The optimization of drug delivery with iontophoresis
Bhat et al. Pharmacology & Pharmacotherapeutics
Jiali et al. Phenomenological analysis of drug transport through stratum corneum

Legal Events

Date Code Title Description
MKLA Lapsed